Head-and-neck cancer patients who received Oncolytics Biotech's Reolysin, together with carboplatin and paclitaxel, survived a median of 94 days without their disease worsening versus an average of 50 days for patients who got chemotherapy alone, a Phase III trial showed. Oncolytics said the combination, which is also under development for lung cancer, was safe and well-tolerated.

Full Story:

Related Summaries